Zelira Therapeutics brings deep
pharmaceutical expertise to the
development and commercialisation of our
proprietary cannabinoid-based medicines.
Zelira Therapeutics…with our focus on specific
conditions, we are ‘reimagining healthcare’
for millions of people underserved by
We are committed to building patient and
doctor confidence in our medicines with
an ethical, evidence-based approach,
applying world-class science and
conducting clinical trials.
Zelira Therapeutics - Global Leader in cannabinoid-based medicine
Zelira Therapeutics Ltd is a leading global cannabinoid-based biopharmaceutical company with access to the world’s largest and fastest growing markets. Zelira owns a portfolio of proprietary revenue generating products and a pipeline of candidates undergoing clinical development that are positioned to enter global markets. The Company is focused on developing branded cannabinoid-based medicines for the treatment of a variety of medical conditions in its Rx business, including insomnia, autism and chronic non-cancer pain.
Recent Video and Audio from Zelira Therapeutics
Chairman Osagie Imasogie and CEO Oludare Odumosu lead a presentation on the creation of an SPV and US $8.6M cornerstone funding from Cantheon Capital LLC for HOPE 1 Ph.2 and Ph.3 US FDA clinical trials.
Zelira Therapeutics Chairman Osagie Imasogie and Global CEO Oludare Odumosu present a company update at the 2022 Annual General Meeting.
Zelira Global CEO Oludare Odumosu provides Proactive with an update on the company’s progress with its proprietary revenue-generating products, global expansion and its pipeline of candidates undergoing clinical development.
Hear the latest business updates from Zelira Therapeutics Chairman Osagie Imasogie and Global CEO Dr Oludare Odumosu.
Zelira Therapeutics Chairman Osagie Imasogie and Global CEO Dr Oludare Odumosu deliver a slide presentation and answer investor questions as part of a business update.
Zelira product helping young patient with autism spectrum disorder